Assessing Phase 2 Data on Bepranemab’s Effect on Tau Accumulation and Cognitive Function: Matthew Barton, PhD

The head of global clinical development for immunology/bone at talked about findings presented at CTAD 2024 from the phase 2 trial assessing bepranemab in Alzheimer disease. [WATCH TIME: 3 minutes]:

Source: Neurology Read More

Previous PostAvidity Biosciences Initiates Biomarker Cohort in Phase 1/2 FORTITUDE Trial, Seeks Accelerated Approval Path for AOC 1020
Next PostWhy Elephants Don’t Get Cancer but Ferrets Do: Cancer Prevalence Across Vertebrate Animals

Assessing Phase 2 Data on Bepranemab’s Effect on Tau Accumulation and Cognitive Function: Matthew Barton, PhD

Previous PostAvidity Biosciences Initiates Biomarker Cohort in Phase 1/2 FORTITUDE Trial, Seeks Accelerated Approval Path for AOC 1020

Next PostWhy Elephants Don’t Get Cancer but Ferrets Do: Cancer Prevalence Across Vertebrate Animals

Related Posts

<![CDATA[Donanemab Shows Durable Amyloid Clearance and Consistent Safety in Early-Start Patients]]>

<![CDATA[Masterclass at AMTRD Highlights Real-World Applications of Botulinum Toxin in Movement Disorders: Laxman Bahroo, MD]]>

<![CDATA[Fenebrutinib Demonstrates Strong Efficacy, Favorable Safety in FENhance MS Trials: Jacqueline Nicholas, MD]]>

Categories